Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents

被引：69

作者：

Doherty, AM ^{[1
]}

机构：

[1] Inst Rech Jouveinal Parke Davis, F-94265 Fresnes, France

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 1999年 / 3卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(99)80068-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Preclinical and clinical studies of phosphodiesterase 4 inhibitors have shown that these agents may find utility in a wide range of inflammatory disorders, including asthma, chronic obstructive pulmonary disease, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and various neurological disorders. The future of this class of drugs will depend upon the ability to demonstrate a reasonable safety margin against emesis and other typical phosphodieserase (PDE4) side effects, as well as in identification of the inflammatory disorder(s) most relevant to PDE4 inhibition.

引用

页码：466 / 473

页数：8